Argos Therapeutics to Present at the World Stem Cells Regenerative Medicine Congress 2015

DURHAM, N.C., May 20, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, today announced that Dr. Charles Nicolette, the company's chief scientific officer and vice president of research and development, and Dr. Fred Miesowicz, the company's chief operating officer and vice president of manufacturing, will present at the World Stem Cells Regenerative Medicine Congress being held at the Business Design Centre in London May 20-22, 2015.

Dr. Nicolette is scheduled to speak during the "Spotlight on T-Cells" session on Thursday, May 21st, beginning at 3:30pm BST. The presentation, titled, "The Arcelis® immuno-oncology platform: A weapon of (tumor) mass destruction powered by T-cells," will include an overview of Argos's alternative to the adoptive transfer of T-cells and insights on how the company is addressing strategic challenges of working with dendritic cells.

Dr. Miesowicz will participate in the "Plenary Roundtables: Biotechs" session on Thursday, May 21st, beginning at 11:30am BST, where he will discuss the logistics of commercializing personalized cell therapy with scale-out potential and quality control. Dr. Miesowicz will also participate in a panel discussion during the "Implementing Industrialization through Cost-Effective Methods" session on Thursday, May 21st, beginning at 4:50pm BST. The panel is titled, "Best practices when industrializing the link between equipment and disposables," and will cover how Argos's automated manufacturing process with the use of disposables applies to general cell therapy production.

The World Stem Cells Regenerative Medicine Congress launched in 2005 and convenes industry leaders to discuss the latest developments in translational research and best practices for business development and the commercialization of cell therapy, regenerative medicine, and tissue engineering. For more information visit

About the Arcelis® Technology Platform

Arcelis® is a fully personalized immunotherapy technology that captures mutated and variant antigens that are specific to each patient's disease. It is designed to overcome immunosuppression by producing a durable memory T-cell response without adjuvants that may be associated with toxicity. The technology is potentially applicable to a wide range of different cancers, and is designed to overcome many of the manufacturing and commercialization challenges that have impeded other personalized cancer immunotherapies. The Arcelis® process uses only a small tumor or blood sample and the patient's own dendritic cells, which are collected and optimized following a single leukapheresis procedure. The proprietary process uses RNA isolated from the patient's disease sample to program dendritic cells to target disease specific antigens. The activated, antigen-loaded dendritic cells are then formulated into the patient's plasma and administered via intradermal injection.

About Argos Therapeutics

Argos Therapeutics is an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer using its Arcelis® technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The Company is also developing a separate Arcelis®-based product candidate, AGS-004, for the treatment of HIV, currently being evaluated in a phase 2 clinical trial aimed at HIV eradication in adult patients. For more information about Argos Therapeutics, visit

Forward Looking Statements

Any statements in this press release about Argos' future expectations, plans and prospects, including statements about Argos and other statements containing the words "believes," "anticipates," "plans," "expects," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including whether Argos' cash resources will be sufficient to fund our continuing operations for the period anticipated; whether results obtained in clinical trials will be indicative of results obtained in future clinical trials; whether Argos' product candidates will advance through the clinical trial process on a timely basis and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if product candidates obtain approval, they will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of Argos' Annual Report on Form 10-K for the year ended December 31, 2014 which is on file with the SEC. In addition, the forward-looking statements included in this press release represent Argos' views as of May 20, 2015. Argos anticipates that subsequent events and developments will cause Argos' views to change. However, while Argos may elect to update these forward-looking statements at some point in the future, Argos specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Argos' views as of any date subsequent to May 20, 2015.

CONTACT: Media contact: Adam Daley Berry & Company Public Relations 212-253-8881 Investor contact: Nancy Yu Burns McClellan 212-213-0006

Source:Argos Therapeutics, Inc.